These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 33819752)

  • 41. Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE.
    Mamounas EP; Untch M; Mano MS; Huang CS; Geyer CE; von Minckwitz G; Wolmark N; Pivot X; Kuemmel S; DiGiovanna MP; Kaufman B; Kunz G; Conlin AK; Alcedo JC; Kuehn T; Wapnir I; Fontana A; Hackmann J; Polikoff J; Saghatchian M; Brufsky A; Yang Y; Zimovjanova M; Boulet T; Liu H; Tesarowski D; Lam LH; Song C; Smitt M; Loibl S
    Ann Oncol; 2021 Aug; 32(8):1005-1014. PubMed ID: 33932503
    [TBL] [Abstract][Full Text] [Related]  

  • 42. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.
    Harbeck N; Gluz O; Christgen M; Kates RE; Braun M; Küemmel S; Schumacher C; Potenberg J; Kraemer S; Kleine-Tebbe A; Augustin D; Aktas B; Forstbauer H; Tio J; von Schumann R; Liedtke C; Grischke EM; Schumacher J; Wuerstlein R; Kreipe HH; Nitz UA
    J Clin Oncol; 2017 Sep; 35(26):3046-3054. PubMed ID: 28682681
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The EMA review of trastuzumab emtansine (T-DM1) for the adjuvant treatment of adult patients with HER2-positive early breast cancer.
    Delgado J; Vleminckx C; Sarac S; Sosa A; Bergh J; Giuliani R; Enzmann H; Pignatti F
    ESMO Open; 2021 Apr; 6(2):100074. PubMed ID: 33647599
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer.
    Lu D; Li C; Riggs M; Polhamus D; French J; Agarwal P; Chen SC; Vadhavkar S; Patre M; Strasak A; Quartino A; Jin JY; Girish S
    Cancer Chemother Pharmacol; 2019 Jul; 84(1):175-185. PubMed ID: 31102024
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Patterns of Care and Clinical Outcomes of First-Line Trastuzumab-Based Therapy in HER2-Positive Metastatic Breast Cancer Patients Relapsing After (Neo)Adjuvant Trastuzumab: An Italian Multicenter Retrospective Cohort Study.
    Lambertini M; Ferreira AR; Poggio F; Puglisi F; Bernardo A; Montemurro F; Poletto E; Pozzi E; Rossi V; Risi E; Lai A; Zanardi E; Sini V; Ziliani S; Minuti G; Mura S; Grasso D; Fontana A; Del Mastro L
    Oncologist; 2015 Aug; 20(8):880-9. PubMed ID: 26099741
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Trastuzumab emtansine for HER2-positive advanced breast cancer.
    Verma S; Miles D; Gianni L; Krop IE; Welslau M; Baselga J; Pegram M; Oh DY; Diéras V; Guardino E; Fang L; Lu MW; Olsen S; Blackwell K;
    N Engl J Med; 2012 Nov; 367(19):1783-91. PubMed ID: 23020162
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial.
    Hurvitz SA; Kim SB; Chung WP; Im SA; Park YH; Hegg R; Kim MH; Tseng LM; Petry V; Chung CF; Iwata H; Hamilton E; Curigliano G; Xu B; Egorov A; Liu Y; Cathcart J; Bako E; Tecson K; Verma S; Cortés J
    ESMO Open; 2024 May; 9(5):102924. PubMed ID: 38796287
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer.
    Van Raemdonck E; Floris G; Berteloot P; Laenen A; Vergote I; Wildiers H; Punie K; Neven P
    Breast Cancer Res Treat; 2021 Jan; 185(1):183-194. PubMed ID: 32980945
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of prior (neo)adjuvant trastuzumab (NAT) exposure on the efficacy of HER2-targeted therapy for metastatic breast cancer.
    Kanjanapan Y; Lok SW; Gibbs P; De Boer R; Yeo B; Greenberg S; Barnett F; Knott L; Richardson G; Wong R; Nottage M; Collins IM; Torres J; Lombard J; Johns J; Harold M; Malik L
    Breast Cancer Res Treat; 2020 Nov; 184(1):87-95. PubMed ID: 32779037
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Economic evaluation of adjuvant trastuzumab emtansine in patients with HER2-positive early breast cancer and residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment in Canada.
    Younis T; Lee A; Coombes ME; Bouganim N; Becker D; Revil C; Jhuti GS
    Curr Oncol; 2020 Dec; 27(6):e578-e589. PubMed ID: 33380873
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and Safety of Gemcitabine With Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Phase 2 Clinical Trial.
    Iyengar NM; Smyth LM; Lake D; Gucalp A; Singh JC; Traina TA; DeFusco P; Fornier MN; Goldfarb S; Jhaveri K; Modi S; Troso-Sandoval T; Patil S; Ulaner GA; Jochelson M; Norton L; Hudis CA; Dang CT
    JAMA Netw Open; 2019 Nov; 2(11):e1916211. PubMed ID: 31774522
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Trastuzumab retreatment after relapse on adjuvant trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer: final results of the Retreatment after HErceptin Adjuvant trial.
    Láng I; Bell R; Feng FY; Lopez RI; Jassem J; Semiglazov V; Al-Sakaff N; Heinzmann D; Chang J
    Clin Oncol (R Coll Radiol); 2014 Feb; 26(2):81-9. PubMed ID: 24051172
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Real-world effectiveness of post-trastuzumab emtansine treatment in patients with HER2-positive, unresectable and/or metastatic breast cancer: a retrospective observational study (KBCSG-TR 1917).
    Nakayama T; Yoshinami T; Yasojima H; Kittaka N; Takahashi M; Ohtani S; Kim SJ; Kurakami H; Yamamoto N; Yamada T; Takata T; Masuda N
    BMC Cancer; 2021 Jul; 21(1):795. PubMed ID: 34238257
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Case series of docetaxel, trastuzumab, and pertuzumab (DTP) as first line anti-HER2 therapy and ado-trastuzumab emtansine (T-DM1) as second line for recurrent or metastatic HER2-positive salivary duct carcinoma.
    Uijen MJM; Lassche G; van Engen-van Grunsven ACH; Driessen CML; van Herpen CML
    Oral Oncol; 2022 Feb; 125():105703. PubMed ID: 34995931
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Trastuzumab emtansine vs lapatinib and capecitabine in HER2-positive metastatic breast cancer brain metastases: A real-world study.
    Sanglier T; Shim J; Lamarre N; Peña-Murillo C; Antao V; Montemurro F
    Breast; 2023 Jun; 69():441-450. PubMed ID: 36709091
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Trastuzumab emtansine plus pertuzumab in Japanese patients with HER2-positive metastatic breast cancer: a phase Ib study.
    Noguchi E; Tamura K; Hattori M; Horiguchi J; Sato N; Kanatani K; Matsunaga K; Iwata H; Fujiwara Y
    Breast Cancer; 2019 Jan; 26(1):39-46. PubMed ID: 30039339
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks).
    Takano T; Masuda N; Ito M; Inoue K; Tanabe Y; Kawaguchi K; Yasojima H; Bando H; Nakamura R; Yamanaka T; Ishida K; Aruga T; Yanagita Y; Tokunaga E; Aogi K; Ohno S; Kasai H; Kataoka TR; Morita S; Toi M
    Breast Cancer Res Treat; 2024 Aug; 207(1):33-48. PubMed ID: 38767786
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparative effectiveness of trastuzumab emtansine versus lapatinib plus chemotherapy for HER2+ metastatic breast cancer.
    Ramagopalan SV; Pisoni R; Zenin A; Rathore LS; Ray J; Sammon C
    J Comp Eff Res; 2021 May; 10(7):595-602. PubMed ID: 33095031
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
    Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
    Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy of the eribulin, pertuzumab, and trastuzumab combination therapy for human epidermal growth factor receptor 2-positive advanced or metastatic breast cancer: a multicenter, single arm, phase II study (JBCRG-M03 study).
    Yamashita T; Kawaguchi H; Masuda N; Kitada M; Narui K; Hattori M; Yoshinami T; Matsunami N; Yanagihara K; Kawasoe T; Nagashima T; Bando H; Yano H; Hasegawa Y; Nakamura R; Kashiwaba M; Morita S; Ohno S; Toi M
    Invest New Drugs; 2021 Feb; 39(1):217-225. PubMed ID: 32833136
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.